Cetuximab, a chimeric monoclonal antibody againts epidermal growth factor receptor (EGFR), is increasingly used to treat tumors that overexpress this receptor as squamous cell cancer of the head and neck (SCCHN), colon and non-small-cell lung cancers. The most common side effects of anti-EGFR are acneiform rash, xerosis, paronychia, teleangiectasia and itch. We report the unusual case of a patient with SCCHN in whom treatment with cetuximab led to development of multiple cutaneous abscesses.
|Number of pages||2|
|Journal||European Journal of Dermatology|
|Publication status||Published - 2013|